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Abstract:  High doses of the recreational drug 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) have been 
well-documented to reduce the expression of serotonergic markers in several forebrain regions of rats and nonhuman pri-
mates. Neuroimaging studies further suggest that at least one of these markers, the plasma membrane serotonin transporter 
(SERT), may also be reduced in heavy Ecstasy users. Such effects, particularly when observed in experimental animal 
models, have generally been interpreted as reflecting a loss of serotonergic fibers and terminals following MDMA expo-
sure. This view has been challenged, however, based on the finding that MDMA usually does not elicit glial cell reactions 
known to occur in response to central nervous system (CNS) damage. The aim of this review is to address both sides of 
the MDMA-neurotoxicity controversy, including recent findings from our laboratory regarding the potential of MDMA to 
induce serotonergic damage in a rat binge model. Our data add to the growing literature implicating neuroregulatory 
mechanisms underlying MDMA-induced serotonergic dysfunction and questioning the need to invoke a degenerative  
response to explain such dysfunction. 
Keywords: MDMA, serotonin, neurodegeneration, neurotoxicity, serotonin transporter, vesicular monoamine transporter 2, 
gene expression, biochemical downregulation. 
INTRODUCTION 
  The recreational drug 3,4-methylenedioxymethamphet-
amine (MDMA; “Ecstasy”) is a ring-substituted ampheta-
mine in the phenylisopropylamine family of substances [1]. 
MDMA is categorized as an “entactogen” primarily due to 
its empathogenic effects in human users, which accounts for 
its early clinical use from the late 1960’s through the late 
1970’s as an adjunct to psychotherapy [2]. The use of this 
substance soon spread to the general population, and despite 
its reported utility in the therapeutic setting, MDMA and the 
related compound 3,4-methylenedioxyamphetamine (MDA) 
were given a Schedule 1 designation due to their reputedly 
high abuse potential, lack of assessed safety for use under 
medical supervision, and emerging evidence suggesting 
“neurotoxic” effects of these compounds in animals, particu-
larly on the serotonergic neuromodulatory system in the 
brain [3, 4]. However, the exact nature of these effects has 
proven difficult to determine, ineluctably leading to consid-
erable debate on this issue within the drug abuse research 
community. The most critical areas of disagreement have 
involved the definition of what constitutes “neurotoxicity”, 
determination of the mechanism(s) responsible for the ob-
served neurochemical changes following MDMA exposure, 
and the appropriateness of using certain biochemical and 
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histological techniques to assess the capacity of this com-
pound to cause neurodegeneration. More than 20 years later, 
these issues remain unresolved, indicating the need for new 
approaches to enhance our understanding of the adverse ef-
fects of this compound on the serotonergic system. 
EVIDENCE SUPPORTING THE NEURODEGEN-
ERATION HYPOTHESIS 
  The neurodegeneration hypothesis of MDMA (and 
MDA) neurotoxicity first appeared in the published literature 
in the mid-to-late 1980s based on a number of studies in rats 
[5-10] and a few studies in nonhuman primates [3, 11, 12] 
(note: we are excluding mouse studies from this review be-
cause mice exhibit a strong dopamine (DA) neurotoxicity in 
response to MDMA that is largely absent in rats and mon-
keys). In most of the rat studies, MDMA was administered 
either in a single dose ranging from 10 to 40 mg/kg or in 
multiple doses of 10 or 20 mg/kg MDMA over several con-
secutive days. “Neurotoxicity” was assessed at 1-2 weeks 
after the final drug treatment by measuring changes in fore-
brain levels of serotonin (5-hydroxytryptamine, 5-HT), DA, 
norepinephrine (NE), and their respective major metabolites 
or, in some cases, changes in synaptosomal monoamine up-
take or radiolabeled transporter binding. These studies con-
sistently revealed major decrements in 5-HT and 5-
hydoxyindoleacetic acid (5-HIAA) levels following MDMA 
exposure, with very modest, if any, effects on levels of the 
other monoamine neurotransmitters. Similarly, 5-HT uptake 
and 5-HT transporter (SERT) binding were significantly 
reduced in response to high-dose MDMA treatment regi-
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subsequently shown to depend on a variety of factors, in-
cluding dosing regimen, route of administration, which enan-
tiomer of MDMA is administered, and inter-species differ-
ences in ADME (absorption, distribution, metabolism, and 
excretion) profiles [4]. The effect of ambient temperature is 
also of particular importance, in that exposure to the drug at 
higher temperatures (>21-23°C) usually causes hyperthermia 
and an exacerbation of neurotoxic effects, whereas exposure 
at lower temperatures (<19-21°C) tends to yield a hypother-
mic response and an attenuation of these effects [13]. At 
around 21°C, previous findings from our laboratory indicate 
that the dysregulatory effects of MDMA on body tempera-
ture cause some animals to become hyperthermic while oth-
ers exhibit a hypothermic response [14]. 
   The ability of a high-dose MDMA treatment regimen to 
produce long-lasting reductions not only in tissue 5-HT and 
5-HIAA content but also in 5-HT reuptake and SERT bind-
ing is significant because the SERT protein is selectively 
expressed by serotonergic neurons and is found in the plasma 
membrane of serotonergic axons and terminals. Conse-
quently, decreases in the amount of SERT (measured either 
by radioligand binding or using an uptake assay) after 
MDMA exposure could be indicative of compromised ax-
onal and nerve terminal integrity. In fact, many studies have 
now demonstrated dramatic decreases in SERT binding fol-
lowing various MDMA dosing regimens and post-adminis- 
tration periods of analysis [4]. Importantly, these analyses 
have also demonstrated the effect of MDMA on 5-HT and 
SERT depletion to be region specific. For example, areas 
such as the striatum, hippocampus, and cortex seem to be 
affected more strongly than some other areas such as the 
hypothalamus or certain thalamic nuclei [15]. 
  Some of the most powerful evidence offered in support 
of the neurodegeneration hypothesis comes from studies 
involving immunohistochemical (IHC) visualization of sero-
tonergic fibers. Most IHC studies have used antibodies 
against 5-HT itself, though a few have stained for SERT or 
tryptophan hydroxylase (TPH), the rate-limiting enzyme in 
the biosynthesis of 5-HT [16-20]. Early on, researchers re-
ported evidence for transient MDMA-induced swelling and 
fragmentation of 5-HT-immunoreactive fibers in the rat 
forebrain followed shortly by a disappearance of many of 
these fibers [7, 21]. Fine-caliber axons believed to originate 
from the dorsal raphe nuclei (DRN) seemed to be particu-
larly vulnerable to these effects, in contrast to the larger vari-
cose axons believed to originate from the median raphe nu-
clei (MRN) that were mainly spared from the drug-induced 
insult. Not surprisingly, these findings were interpreted as 
showing that high doses of MDMA rapidly damage ascend-
ing serotonergic projections (manifested by the swollen ap-
pearance of the fibers at early time points), which is followed 
by a degeneration of the damaged axons and terminals 
(manifested by their disappearance at later time points). Im-
portantly, MDMA was not found to decrease the number of 
5-HT-immunoreactive cells within the raphe nuclei, suggest-
ing that this compound causes a degeneration of forebrain 
serotonergic fibers (i.e., distal axotomy) without inducing 
cellular death. 
  Long-term studies using either IHC or SERT autoradio-
graphy have demonstrated gradual post-MDMA recovery of 
serotonergic fiber density (based on a reappearance of 
stained fibers or an increase in SERT binding back to normal 
levels). Depending on the MDMA dosing regimen, brain 
area, and species studied, significant (even full) recovery 
may occur anywhere from 8 weeks to a full year (e.g., see 
[15, 22]). Nevertheless, studies from Ricaurte’s group have 
shown incomplete recovery in certain brain areas and/or in 
particular animals as far out as 12-18 months post-treatment 
[23, 24]. Another important finding from these time course 
studies is the late appearance of a serotonergic hyperinnerva-
tion of certain subcortical brain areas, a phenomenon thought 
to reflect axonal/terminal sprouting following synaptic loss 
[18, 23, 25]. 
  Finally, several other kinds of experimental findings have 
been offered in support of the neurodegeneration hypothesis. 
First, there are reports of MDMA-induced damage to axons, 
terminals, and cell bodies in a few forebrain areas based on 
well-established markers of neurodegeneration such as silver 
impregnation and Fluoro-Jade B staining [6, 26, 27, 28]. 
Second, Callahan and coworkers [29] found a reduction in 
[
3H] proline anterograde transport from the raphe nuclei to 
forebrain structures following MDMA treatment, which 
could reflect a loss of rostrally projecting serotonergic fibers. 
Finally, there is substantial evidence that MDMA can pro-
voke significant increases in oxidative stress in the brain, 
which is one of the proposed mechanisms by which this 
compound could produce neurodegenerative effects [30, 31]. 
Nevertheless, caveats can be raised regarding each of these 
findings. With respect to the above mentioned markers of 
neurodegeneration, these markers are non-specific and in 
fact, serotonergic axons are not very sensitive to silver im-
pregnation methods [7]. In addition, the relatively limited 
distribution of silver staining compared to the widespread 
loss of 5-HT immunoreactivity throughout much of the ros-
tral forebrain (i.e., cortex, hippocampus, and striatum) raises 
serious doubts about whether the degenerating axons seen in 
MDMA-treated animals are actually serotonergic (note also 
that due to the absence of serotonergic cell bodies in the 
forebrain, degenerating cells in this region are also presuma-
bly non-serotonergic). A similar issue of non-specificity ap-
plies to the drug-induced reduction in anterograde transport, 
since the cell populations within the rostral raphe are known 
to be highly heterogeneous [32]. Thus, indices of neurode-
generation or of axonal integrity (i.e., anterograde or retro-
grade transport) need to be bolstered with appropriate immu-
nohistochemical markers of serotonergic neurons to confirm 
the identity of the degenerating fibers or cells. Indeed, a re-
cent study by Kovács et al. [17] found MDMA-induced de-
creases in serotonergic fiber density assessed by means of 
either TPH or SERT immunostaining, yet there was no evi-
dence for a blockage of fast axonal transport in the remain-
ing visible TPH-immunoreactive fibers. As a final point, 
there seems to be little doubt that high doses of MDMA 
cause increased oxidative stress as well as other conse-
quences that are likely to produce significant cellular dys-
function. What remains unclear, however, is whether these 
effects occur selectively in serotonergic neurons and whether 
this ultimately leads to the distal axotomy proposed by the 
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EVIDENCE AGAINST THE NEURODEGENERATION 
HYPOTHESIS 
  Although the neurodegeneration hypothesis has domi-
nated the MDMA neurotoxicity field for over two decades, 
findings have appeared in the literature that are inconsistent 
with this view. One problematic area concerns whether or 
not MDMA causes glial responses considered to be charac-
teristic of CNS injury. O’Callaghan and Miller were the first 
researchers to measure glial responses to MDMA insult. 
They examined the dose-dependent effects of MDMA in rats 
on regional levels of glial fibrillary acidic protein (GFAP), 
an astroglial structural protein previously shown to be ele-
vated as a consequence of CNS damage-induced astrocyte 
hypertrophy. At doses up to 30 mg/kg given twice daily, 
there were no increases in GFAP in the cortex, hippocampus, 
or striatum measured 2 days after the last drug dose, despite 
massive 5-HT depletions in the same brain areas [33]. In-
creased GFAP levels were finally observed in the cortex and 
striatum when the animals were administered 75-150 mg/kg 
twice daily MDMA for 2 days; however, even at those ex-
treme doses there was no change in GFAP in the hippocam-
pus. A positive control experiment with the established sero-
tonergic neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) 
demonstrated significant elevations in GFAP levels in all 
brain areas studied, which coincided with the 5-HT-depleting 
effects of the treatment. Several later studies by other inves-
tigators found a similar lack of effect of “neurotoxic” 
MDMA doses on measures of either astroglial (GFAP ex-
pression or cleaved-tau immunoreactivity) or microglial 
([
3H] PK-11195 binding, OX-6 immunoreactivity, or HSP32 
expression) reactivity [34-37], although contrary findings 
have been reported in several instances [16, 38, 39]. Overall, 
despite the presence of some inconsistencies in the literature, 
there is substantial evidence that MDMA doses that produce 
substantial, long-lasting reductions in 5-HT and other sero-
tonergic markers do not reliably provoke astroglial or micro-
glial responses, thus questioning whether such reductions 
truly reflect structural damage to the serotonergic system. 
  Two other recent studies provide evidence that is incon-
sistent with a loss of serotonergic fibers and terminals fol-
lowing MDMA. Wang et al. [40] showed that the apparent 
loss of forebrain serotonergic projections (determined by 
immunoautoradiography) following MDMA treatment in rats 
could be restored when the animals were given the 5-HT 
precursor 5-hydroxytryptophan (5-HTP) prior to tissue 
analysis. This finding suggests that serotonergic fibers may 
remain intact following MDMA exposure, but that MDMA-
induced reduction of 5-HT pools within these axons and ter-
minals preclude their detection by immunological staining 
methods. However, it should be noted that because 5-HTP 
can be converted to 5-HT in all monoaminergic neurons by 
the enzyme aromatic L-amino acid decarboxylase, this “res-
toration” could be due at least partially to staining of 5-HT-
containing dopaminergic and/or noradrenergic fibers that 
were not visualized prior to the 5-HTP treatment. A different 
approach was taken by Callaghan and coworkers [41], who 
measured the effects of MDMA on 5-HT clearance in vivo in 
the hippocampal CA3 region using chronoamperometry. 
Despite significant drug-induced decreases in hippocampal 
5-HT content, in vitro 5-HT uptake measured in synaptoso-
mal preparations, and SERT binding in the CA3 area, there 
was no change in 5-HT clearance in vivo. Interestingly, p-
methoxyamphetamine, another neurotoxic amphetamine, did 
cause a reduction in in vivo 5-HT clearance measured 2 
weeks after dosing. Although there are several possible in-
terpretations of the MDMA results, such results again sug-
gest that SERT-expressing axons and terminals in the hippo-
campus may remain intact following MDMA, although for 
reasons as yet unknown, expression and functioning of the 
transporter appear compromised when assessed by standard 
in vitro binding and uptake assays. 
TOWARDS RECONCILING THE NEUROTOXICITY 
CONTROVERSY 
  At least some of the debate regarding the nature of 
MDMA-induced serotonergic dysfunction is due to a lack of 
consensus regarding the definition of drug-neurotoxicity, 
specifically a failure to distinguish between substances that 
merely deplete marker proteins within intact neurons and 
those that cause measurable neurodegeneration. This is an 
important distinction to consider since drug-induced neu-
rodegeneration is more likely to cause irreparable conse-
quences for neurobehavioral functioning. Given the plethora 
of evidence showing the 5-HT- and SERT-depleting effects 
of MDMA, this substance can certainly be considered “neu-
rotoxic” in terms of causing serotonergic dysfunction. The 
question at hand, however, is whether serotonergic marker 
depletion by MDMA is reflective of neurodegeneration or 
rather is an effect of biochemical downregulation in the ab-
sence of tissue damage. 
  While most investigators in this field equate MDMA-
induced reductions in serotonergic markers with a neurode-
generative process, this interpretation can be challenged. For 
example, although post-MDMA decreases in SERT binding 
as well as SERT-, TPH-, and 5-HT-immunoreactive fiber 
density may indeed result from loss of serotonergic fibers, it 
should be underscored that such analyses depend on the 
binding of radioligands and antibodies, respectively, to pro-
teins that may be liable to regulation by MDMA (of course, 
5-HT is also included here, since its synthesis depends on the 
presence of active TPH enzyme). For example, as discussed, 
MDMA causes a depletion of both TPH and 5-HT, perhaps 
reducing levels of these antigens in IHC studies to below 
thresholds for detection, thus only giving the appearance of 
missing fibers. In the long-term, some evidence suggests that 
SERT gene expression may be negatively regulated by 
MDMA exposure [42], which could lead to reductions in 
SERT binding and immunoreactive fiber density in the ab-
sence of physical damage. Additionally, since binding assays 
typically make use of plasma membrane preparations, it is 
possible that MDMA-induced enhancement of SERT traf-
ficking by endocytosis [43] could lead to decreases in plas-
malemmal SERT binding irrespective of altered terminal 
integrity (although this possibility remains speculative at the 
present time). As such, it is important to appreciate that 
MDMA-induced serotonergic deficits can be explained by 
factors not necessarily dependent on axonal damage. 
  Recent studies in our laboratory have been aimed at pro-
viding new information bearing on the issue of MDMA neu-
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the literature concerning whether or not “neurotoxic” doses 
of MDMA lead to reductions in SERT expression by im-
munoblotting. This controversy arose when two studies by 
Wang et al. [36, 37] found no changes in SERT protein ex-
pression in MDMA-treated animals when expression was 
measured by this method. This surprising result occurred 
despite substantial drug-induced reductions in 5-HT levels 
and SERT binding, the typical method for assessing 
MDMA-related reductions in SERT expression. Subse-
quently, Xie and colleagues [20] reported decreased SERT 
protein by immunoblotting following high-dose MDMA 
treatment, as well as a reduction in the density of SERT-
immunoreactive fibers using two different antibodies (one of 
which was the same as that used for the immunoblotting pro-
cedure). In an attempt to help resolve this discrepancy, we 
conducted our own immunoblotting study of SERT using an 
approach similar to that of Xie et al. [20] in that we per-
formed several positive control procedures to validate our 
SERT immunoblotting methods prior to assessing the effects 
of MDMA on expression of this protein. Specifically, by 
using tissue sources known to contain different amounts of 
the protein (i.e., parietal cortex and hippocampus from wild-
type mice versus SERT-knockout mice; hippocampus from 
saline- versus 5,7-DHT-treated rats; and various brain re-
gions with differential expression of SERT protein), we 
screened several different commercially-available anti-SERT 
antibodies for their ability to yield authentic SERT protein 
bands as distinguished by the expected changes in band den-
sity relative to other, presumably non-specific, bands. Al-
though several of the antibodies tested failed our screening 
methods (see [44] for details), we did identify one antibody 
that generated a valid band in the range of ~76 kDa [44], 
which is consistent with the predicted molecular weight of 
glycosylated plasmalemmal SERT protein [45]. When we 
subsequently used this validated procedure to investigate 
SERT protein expression in whole-tissue lysate preparations 
2 weeks following an MDMA binge regimen (4 x 10 mg/kg), 
expression was profoundly reduced in the striatum, hippo-
campus, and cortex [44]. These findings are consistent with 
the extensive radioligand binding literature discussed earlier 
showing that high doses of MDMA lead to large decreases in 
SERT in a number of different forebrain areas.  
  We next asked whether or not MDMA similarly affected 
the expression of two other proteins present in serotonergic 
nerve terminals, namely TPH and the vesicular monoamine 
transporter 2 (VMAT-2). For this experiment, we chose to 
study synaptosomal preparations instead of whole tissue 
lysates, and TPH and VMAT-2 immunoblotting methods 
were again validated by appropriate control procedures. The 
use of VMAT-2 as a marker for potential MDMA-induced 
terminal loss was particularly advantageous for two reasons. 
First, as a vesicle-specific protein, VMAT-2 is highly con-
centrated in monoamine nerve terminals. Second and more 
importantly, studies on the dopaminergic system have shown 
a loss of VMAT-2 in terminal fields (i.e., striatum) both fol-
lowing administration of a DA neurotoxin such as metham-
phetamine (METH) [46] and in Parkinson’s disease where 
the DA nerve terminals have undergone massive degenera-
tion [47]. Thus, the additional quantification of VMAT-2 
allowed us to determine whether MDMA-induced changes in 
SERT levels are accompanied by changes in an established 
marker of terminal integrity [48]. A similar approach was 
used by Guilarte and coworkers [49] to distinguish between 
axotomy versus neuronal plasticity in different brain regions 
following METH treatment. Of course, a significant limita-
tion in using VMAT-2 as an index of serotonergic terminal 
density is the additional presence of this protein in noradren-
ergic as well as dopaminergic synaptic vesicles. To minimize 
this problem, we adopted the combined approach of (1) fo-
cusing on the hippocampus since this structure has a rela-
tively sparse dopaminergic innervation (and therefore only a 
minor DA contribution to VMAT-2) [50], and (2) lesioning 
the ascending noradrenergic projections from the locus coer-
uleus to the forebrain (including the hippocampus) by pre-
treating some of the animals with N-(2-chloroethyl)-N-ethyl-
2-bromobenzylamine (DSP-4), a known NE neurotoxin [51]. 
Rats were pretreated with DSP-4 or saline and then given our 
standard MDMA binge treatment regimen or saline 1 week 
later. Two weeks following the MDMA binge, all animals in 
the MDMA-treated groups showed substantial reductions in 
SERT immunoreactivity in striatal, hippocampal, and corti-
cal synaptosomes compared to saline-treated controls. These 
results corroborated our previous findings of MDMA-
induced SERT reductions in whole-tissue lysates. Interest-
ingly, however, we failed to find a significant effect of 
MDMA on synaptosomal VMAT-2 expression in any brain 
area of any treatment group, including the hippocampus of 
DSP-4 pretreated animals (the condition that offered the 
greatest sensitivity to detecting a loss of serotonergic termi-
nals using the present experimental approach) [44]. Addi-
tionally, we were surprised to find that synaptosomal TPH 
protein levels were completely unaltered in the hippocampus 
of MDMA-treated compared to control animals (Biezonski 
and Meyer, manuscript in preparation). These findings 
strongly suggest that decreases in SERT protein expression 
following high-dose MDMA exposure may occur in the ab-
sence of major terminal loss, presumably as a consequence 
of regulatory changes induced by the drug. 
  To investigate a possible mechanism by which MDMA 
might reduce SERT levels in the absence of axonal damage, 
we subsequently used quantitative RT-PCR to determine the 
effects of this compound on SERT (as well as VMAT-2 and 
TPH-2) gene expression in pooled dorsal and median raphe 
tissue punches. Importantly, both nuclei project serotonergic 
fibers to the hippocampus [32], and both contain very few 
catecholaminergic cell bodies that would be expected to con-
tribute to VMAT-2 gene expression in the tissue samples 
[32, 52]. Two weeks following the same MDMA binge 
regimen used in the immunoblotting studies, we found a 
striking, 50-fold reduction in SERT gene expression within 
the dorsal/median raphe, with smaller albeit significant (10-
15-fold) reductions in expression of both the VMAT-2 and 
TPH-2 genes [44]. Although not conclusive, these data none-
theless strongly suggest that MDMA-induced downregula-
tion of SERT gene expression may underlie the reductions in 
SERT protein (measured either by immunoblotting or radio-
ligand binding) consistently seen following treatment with 
this compound. Furthermore, the reduction in VMAT-2 and 
TPH-2 gene expression argue against the possibility that 
compensatory upregulation of gene expression (as a conse-
quence of partial fiber loss) may have normalized protein 
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again supporting the notion that SERT protein depletion re-
sulting from MDMA exposure may indeed occur independ-
ent of axotomy. 
  Finally, in order to more directly determine whether 
MDMA exposure causes 5-HT synaptic loss, we investigated 
whether an MDMA binge regimen alters the quantity of se-
rotonergic nerve terminals in the hippocampus 2 weeks fol-
lowing drug exposure. This was accomplished by preparing 
synaptosomal fractions and then using flow cytometry to 
measure the number of particles that were double-labeled for 
synaptosomal-associated protein of 25 kDa (SNAP-25, a 
general presynaptic terminal marker) and TPH in MDMA- 
and saline-treated animals. Although flow cytometry is pri-
marily used to characterize and quantify cells according to 
their size, granularity, and expression of fluorescently-
labeled antigens, several groups have shown that the same 
approach can be used to characterize and quantify synapto-
somes obtained from rodent or human brain samples (see, for 
example, [53-56]). We were surprised to find that the quan-
tity of serotonergic synaptosomes defined as mentioned 
above not only was not decreased in the MDMA group, but 
actually showed a significant increase relative to controls 
(Biezonski, Lu, and Meyer, manuscript in preparation). 
These results suggest that MDMA may cause an acute reac-
tive synaptogenesis which, in turn, may help account for the 
long-term hyperinnervation of certain brain regions previ-
ously observed in some MDMA-treated animals [18, 23, 25]. 
Nevertheless, given the novelty of our findings and the cur-
rent absence of corroborative studies, it is important to cau-
tion that our data should at most be considered preliminary 
evidence for an acute effect of MDMA on serotonergic syn-
aptogenesis. Other studies are needed to investigate this issue 
using other experimental approaches, including quantifica-
tion of additional relevant markers such as synaptophysin 
[57], growth-associated protein of 43 kDa (GAP-43, [58]), or 
brain-derived neurotrophic factor [59]. Taken together, based 
on the discrepancy between the present results and previ-
ously published findings involving immunostaining for 5-
HT, SERT, or TPH, we question the use of standard immu-
nohistochemical techniques to address the neurodegenerative 
potential of MDMA, unless investigators can stain for a sero-
tonergic neuron-specific antigen whose expression is shown 
to be unaffected by high-dose MDMA treatment regimens. 
  The major implication of our findings is that MDMA-
induced 5-HT marker depletion may not necessarily result 
from a degenerative response. Nevertheless, given that all of 
our methods for detecting MDMA neurotoxicity in the pre-
sent experiments were indirect (i.e., relied on quantifying 
protein/gene expression of markers liable to regulation) and 
measured at only one time point, our findings do not prove 
unequivocally that the effects of MDMA on serotonergic 
nerve terminals occur in the absence of neurodegeneration. 
They do, however, exemplify the dramatic effects this com-
pound can have on the regulation of several serotonergic 
markers, thus questioning the need to invoke distal axotomy 
as the only explanation for MDMA-induced serotonergic 
dysfunction. As such, future studies should aim to confirm 
our findings by the use of more direct measures not depend-
ent on marker staining. Such experiments should investigate 
ways to directly highlight and subsequently measure changes 
in serotonergic fiber density in response to MDMA, such as 
through the use of anterograde or retrograde tracers, or by 
using reporter genes (e.g., green fluorescent protein) driven 
by promoters active only in 5-HT neurons. 
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